Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- ZLNA.OL
- Price
- 9.00
- Stock movement down
- -0.06 (-0.66%)
- Company name
- Zelluna ASA
- Exchange
- (OL ,
- Currency
- NOK )
- Sector
- Healthcare >Biotechnology
- Market cap
- 184.09M
- Ent value
- 131.76M
- Price/Sales
- -
- Price/Book
- 1.97
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -60.35%
- 3 year return
- -78.83%
- 5 year return
- -55.22%
- 10 year return
- -
Last updated: 2025-11-25
DIVIDENDS
ZLNA.OL does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | 1.97 |
| EV to Sales | - |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 20.45M |
| EPS (TTM) | - |
| FCF per share (TTM) | - |
Income statement
Loading...
Income statement data
| Revenue (TTM) | - |
| Gross profit (TTM) | - |
| Operating income (TTM) | - |
| Net income (TTM) | - |
| EPS (TTM) | - |
| EPS (1y forward) | -7.80 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 76.04M |
| Net receivables | 0.00 |
| Total current assets | 93.70M |
| Goodwill | 0.00 |
| Intangible assets | 17.37M |
| Property, plant and equipment | 5.22M |
| Total assets | 116.93M |
| Accounts payable | 9.51M |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 23.71M |
| Total liabilities | 23.71M |
| Shareholder's equity | 93.22M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | - |
| Capital expenditures (TTM) | - |
| Free cash flow (TTM) | - |
| Dividends paid (TTM) | - |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | - |
| Return on Invested Capital | - |
| Cash Return on Invested Capital | - |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 9.00 |
| Daily high | 9.00 |
| Daily low | 8.70 |
| Daily Volume | 12K |
| All-time high | 1620.00 |
| 1y analyst estimate | - |
| Beta | - |
| EPS (TTM) | - |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 12 Feb 2026 |
Downside potential
Loading...
Downside potential data
| ZLNA.OL | S&P500 | |
| Current price drop from All-time high | -99.44% | -1.80% |
| Highest price drop | -99.46% | -19.00% |
| Date of highest drop | 20 Nov 2025 | 8 Apr 2025 |
| Avg drop from high | -47.97% | -2.73% |
| Avg time to new high | 42 days | 6 days |
| Max time to new high | 1038 days | 89 days |
COMPANY DETAILS
Marketcap
184.09M
Marketcap category
Small-cap
Description
Zelluna ASA develops T-cell receptor (TCR) cellular immunotherapy products for the treatment of solid cancers. The company was founded in 2016 and is based in Oslo, Norway.
Employees
26
Website
Investor relations
-
SEC filings
CEO
Country
Norway
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Oslo, Norway, 17 November, 2025: Reference is made to the stock exchange announcement made by Zelluna ASA (the "Company") on 3 November 2025 regarding the successful private placement of 5,500,000 new...
November 17, 2025
Zelluna ASA (OSL:ZLNA) reports strong capital raise, strategic clinical advancements, and financial challenges in its Q3 2025 earnings call.
November 4, 2025
Oslo, 4 November 2025: Reference is made to the stock exchange notice published by Zelluna ASA (the "Company") on 3 November 2025 regarding the successful private placement and retail offering. The Co...
November 4, 2025
Reference is made to the stock exchange announcement made by Zelluna ASA (the "Company") on 3 November 2025 regarding the allocation of 5,500,000 new shares in the Company in a private placement (the ...
November 4, 2025
Reference is made to the stock exchange announcement made by Zelluna ASA (the "Company") on 3 November 2025 regarding the allocation of 5,500,000 new shares in the Company in a private placement (the ...
November 3, 2025
Successful private placement and retail offering - Zelluna ASA raises NOK 58 million to advance the world’s first “off-the-shelf” TCR-NK therapy, ZI-MA4-1, into Phase I clinical trials and develop the...
November 3, 2025
Zelluna ASA – Contemplates private placement of NOK 50-55 million and retail offering to advance into first-in-human trial of its “off-the-shelf” TCR-NK therapy NOT FOR RELEASE, PUBLICATION OR DISTRIB...
November 3, 2025
Oslo, Norway, 3 November 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic “off-the-shelf” T-cell receptor-based natural killer (TCR-NK) therapies for the treatment of cancer, announces its ...
November 3, 2025
On track to file CTA by year end 2025, with plan to dose first patients and deliver initial data in 2026Planned UK trial to be led by Prof. Fiona Thistlethwaite at The Christie NHS Foundation Trust, a...
October 9, 2025
Oslo, Norway, 10 September 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic ‘off the shelf’ T Cell Receptor based Natural Killer (TCR-NK) cells for the treatment of cancer, announces an Inv...
September 10, 2025
Next page